Bioinformatics: Partnering Deals & Agreements 2016-2023 - Understand Historical Key Deal Terms and Undertake Due Diligence to Assess Suitability of Your Proposed Deal
23 Jun 2023
Radiation Therapy
DUBLIN, June 23, 2023 /PRNewswire/ -- The "Global Bioinformatics Partnering Terms and Agreements 2016 to 2023" report has been added to
ResearchAndMarkets.com's offering.
The Global Bioinformatics Partnering Terms and Agreements 2016 to 2023 report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in bioinformatics partnering deals
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active deal makers
Financial deal terms for bioinformatics
Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2016, including financial terms where available, including over 1600 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading bioinformatics deals since 2016. Deals are listed by headline value, signed by big pharma, most active bioinformatics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in bioinformatics dealmaking with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2016, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2016. The chapter is organized by specific bioinformatics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z, deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.
The report provides the reader with the following key benefits:
In-depth understanding of bioinformatics deal trends since 2016
Access to headline, upfront, milestone and royalty data
Comprehensive access to over 1600 bioinformatics deals entered into by the world's biopharma companies
Detailed access to actual bioinformatics contracts enter into by the leading big pharma companies
Insight into the terms included in a bioinformatics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Companies Mentioned
1QBit
2bPrecise
3D Signatures
111
121nexus
A3 Informatics
Abarca
Abramson Cancer Center
Abyde
Accelq
Accenture
Accuray
AccuWeather
Active Motif
Acuant
Acumen Analytics
Adaptive Research
ADAS 3D Medical
Adents
Adracare
Advaita
Advanced Biological Laboratories
Advanced Clinical
Advanced Guidance Technologies
Advanced Radiation Therapy
Advarra
and many, many more!
For more information about this report visit https://www.researchandmarkets.com/r/bn7c2j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.